Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Revenue (2019 - 2025)

Eton Pharmaceuticals' Revenue history spans 7 years, with the latest figure at $38.2 million for Q3 2025.

  • For Q3 2025, Revenue rose 270.41% year-over-year to $38.2 million; the TTM value through Sep 2025 reached $70.3 million, up 23.0%, while the annual FY2024 figure was $39.0 million, 23.29% up from the prior year.
  • Revenue for Q3 2025 was $38.2 million at Eton Pharmaceuticals, up from $18.9 million in the prior quarter.
  • Across five years, Revenue topped out at $38.2 million in Q3 2025 and bottomed at $775000.0 in Q3 2021.
  • The 5-year median for Revenue is $8.0 million (2024), against an average of $10.1 million.
  • The largest annual shift saw Revenue surged 203200.0% in 2021 before it tumbled 81.71% in 2022.
  • A 5-year view of Revenue shows it stood at $6.1 million in 2021, then surged by 39.47% to $8.5 million in 2022, then skyrocketed by 250.69% to $29.8 million in 2023, then tumbled by 60.92% to $11.6 million in 2024, then skyrocketed by 228.33% to $38.2 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Revenue are $38.2 million (Q3 2025), $18.9 million (Q2 2025), and $1.5 million (Q1 2025).